What question did this study set out to answer?

To investigate the roles of DNMT3A R882 mutations at different stages of acute myeloid leukemia development.

March 4, 2026

Early Driver, Late Bystander: Stage-Specific Roles of DNMT3A R882 Mutations Unveiled in Human AML

Key Points

To investigate the roles of DNMT3A R882 mutations at different stages of acute myeloid leukemia development.
Applied allele-specific CRISPR/Cas9 correction in human AML samples.
Examined the role of DNMT3A R882 mutations in preleukemic and established leukemic cells.
Analyzed self-renewal and inflammatory programs in affected cells.
DNMT3A R882 mutations are essential for self-renewal in preleukemic cells.
Mutations become less necessary once leukemia is established.
DNMT3A mutations still affect the frequency of leukemia stem cells.

Abstract

In this issue, Köhnke, Karigane, and colleagues applied allele-specific CRISPR/Cas9 correction in human acute myeloid leukemia samples to dissect the stage-specific functions of DNA methyltransferase 3A (DNMT3A) arginine 882 (R882) mutations. They demonstrate that DNMT3A R882 mutations are required to sustain self-renewal and inflammatory programs in preleukemic cells but become largely dispensable once leukemia is established, while still influencing leukemia stem cell frequency, thereby providing a strong preclinical rationale to reconsider the therapeutic window for targeting DNMT3A-mutant clones early in leukemogenesis. See related article by Köhnke et al., p. 592.

Bookmark

Cite This Study

Zhou et al. (Mon,) studied this question.

synapsesocial.com/papers/69a7cd0bd48f933b5eed8fe8 https://doi.org/https://doi.org/10.1158/2159-8290.cd-25-2277

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark